Complicated skin and soft tissue infection

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue SUPPL. 3, 2010, Pages

  Dryden, Matthew S ^a  

^a ROYAL HAMPSHIRE COUNTY HOSPITAL   (United Kingdom)

Author keywords

Antibiotic treatment; Daptomycin; Linezolid; Moxifloxacin; MRSA; PVL; Tigecycline

Indexed keywords

BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFTOBIPROLE; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DAPTOMYCIN; ERYTHROMYCIN; LIDAPRIM; LINEZOLID; MOXIFLOXACIN; PANTON VALENTINE LEUKOCIDIN; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; BITE; BURN; CLINICAL TRIAL; COMORBIDITY; DEBRIDEMENT; HUMAN; IMMUNOCOMPROMISED PATIENT; ISCHEMIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NEUTROPENIA; NONHUMAN; PATHOGENESIS; SEPSIS; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; TISSUE NECROSIS; TOXIC SHOCK SYNDROME; TRAVEL;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DEBRIDEMENT; HUMANS; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS;

EID: 77957702965     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq302     Document Type: Article

References (79)

1. Mims C, Playfair J, Roitt I et al. Medical Microbiology. Mosby Int Ltd, London.
2. Dryden MS. Skin and soft tissue infection: microbiology and epidemiology. Int J Antimicrob Agents 2009; Suppl 3: 2-7.
3. Chief Medical Officer's Report 20http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/igitalasset/dh_0962pdf (April 2010, date last accessed)
4. Dryden M, Andrasevic A, Bassetti M et al. A European survey of antibiotic management of methicillin-resistant Staphylococcus aureus infection: current clinical opinion and practice. Clin Microbiol Infect 2010; Suppl 1:3-30.
5. Di Nubile MJ, Lipsky BA. Complicated infections of the skin and skin structures: when the infection is more than skin deep. J Antimicrob Chemother 2004; Suppl 2: ii37-50.
6. Stevens DL, Bisno AL, Chambers H et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41: 1373-406.
7. Eron LJ, Lipsky BA, Low DE et al. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother 2003; Suppl 1: i3-17.
8. FDA. Guidance for Industry: uncomplicated and complicated skin and skin structure infections-developing antimicrobial drugs for treatment. http:/www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071185.pdf (April 2010, date last accessed).
9. Kumar A, Roberts D, Wood KE et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589-96.
10. Diekema DJ, Pfaller MA, Schmitz FJ et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-19Clin Infect Dis 2001; 32: S114-32.
11. Moet GJ, Jones RN, Biedenbach DJ et al. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn Microbiol Infect Dis 2007; 57: 7-13.
12. Jevons MP. Celbenin-resistant staphylococci. Br Med J 1961; 1:124-5.
13. Wenzel RP, Nettleman MD, Jones RN et al. Methicillin-resistant Staphylococcus aureus: implications for the 1990s and effective control measures. Am J Med 1991; 91: 221S-7S.
14. Grundmann H, Aires-de-Sousa M, Boyce J et al. Emergence and resurgence of methicillin-resistant Staphylococcus aureus as a public health threat. Lancet 2006; 368: 874-85.
15. Bruce AM, Spencer JM. Prevalence of community-acquired methicillin-resistant Staphylococcus aureus in a private dermatology office. J Drugs Dermatol 2008; 7: 751-5.
16. Dryden MS. Complicated skin and soft tissue infections caused by MRSA: epidemiology, risk factors and presentation. Surg Infect 2008; Suppl 1:S3-10.
17. Nathwani D, Morgan M, Masterton RG et al. British Society for Antimicrobial Chemotherapy Working Party on Community-onset MRSA Infections. Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community. J Antimicrob Chemother 2008; 61: 976-94.
18. Kaplan SL, Hulten KG, Gonzalez BE et al. Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin Infect Dis 2005; 40: 1785-91.
19. Young DM, Harris HW, Charlebois ED et al. An epidemic of MRSA soft tissue infections among medically underserved patients. Archives Surg 2004; 139: 947-51.
20. Moran GJ, Krishnadasan A, Gorwitz RJ et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355: 666-74.
21. Neapolitano LM. Early appropriate parenteral antimicrobial treatment of complicated skin and soft tissue infections caused by MRSA. Surg Infect 2008; Suppl 1: S17-27.
22. Naimi TS, LeDell KH, Como-Sabetti K et al. Comparison of community and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003; 290: 2976-84.
23. Skiest DJ, Brown K, Cooper TW et al. Prospective comparison of methicillin-susceptible and methicillin-resistant community-associated Staphylococcus aureus infections in hospitalized patients. J Infect 2007; 54:427-34.
24. Wulf MW, Tiemersma E, Kluytmans J et al. MRSA carriage in healthcare personnel in contact with farm animals. J Hosp Infect 2008; 70: 186-90.
25. Grisold AJ, Zarfel G, Stoeger A et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) in Southeast Austria. J Infect 2009; 58: 168-74.
26. VourliS,VagiakouH, GanterisG etal. High rates of community-acquired, Panton-Valentine Leukocidin (PVL)-positive methicillin-resistant S. aureus (MRSA) infections in adult outpatients in Greece. Eurosurveillance 2009; 14:1-4.
27. Miller LG, Perdreau-Remington F, Bayer AS et al. Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: a prospective investigation. Clin Infect Dis 2007; 44: 471-82.
28. Otter JA, French GL. Nosocomial transmission of community-associated methicillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis 2006; 6: 753-5.
29. King MD, Humphrey BJ, Wang YF et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 3clone as the predominant cause of skin and soft tissue infections. Ann Intern Med 2006; 144: 309-17.
30. Awad SS, Elhabash SI, Lee L et al. Increasing incidence of methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: reconsideration of empiric antimicrobial therapy. Am J Surg 2007; 194: 606-10.
31. Moise-Broder PA, Sakoulas G, Eliopoulos GM et al. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004; 38: 1700-5.
32. Saeed K, Dryden M, Parnaby R. Oxacillin-resistant, mecA positive MRSA. J Hosp Infect 2010; doi:10.1016/j.jhin.2010.03.004
33. Dryden MS, Legarde M, Gottlieb T. Vibrio damsela wound infections in Australia. Med J Aust 1989; 151: 540-1.
34. Health Protection Agency. Anthrax alert for heroin users in London. http://ww.hpa.org.uk/webw/HPAweb&HPAwebStandard/HPAweb_C/1265296975679?p=12591524660(April 2010, date last accessed).
35. Dryden MS, Dalgliesh D. Pasteurella multocida from a dog causing Ludwig's angina. Lancet 1996; 347: 123.
36. Dryden MS. A pathogenic role for Bacillus cereus in wound infections in the tropics. J R Soc Med 1987; 80: 480-1.
37. Jones R, Ross J, Stilwell M. Activity of linezolid against a worldwide collection of uncommonly isolated Gram-positive organisms (3,2strains). In: Abstracts of the Seventeenth European Congress of Clinical Microbiology and Infection, Munich, Germany, 20Abstract 1732_European Society for Clinical Microbiology and Infection.
38. Gould IM, Mackenzie FM, Shepherd L. Use of the bacteriology laboratory to decrease general practitioners' antibiotic prescribing. Eur J Gen Pract 2007; 13: 13-5.
39. Dryden MS, Cooke J, Davey P. Antibiotic stewardship - more education and regulation not more availability? J Antimicrob Chemother 2010; 65: 598.
40. Smeets L, Bous A, Heymans O. Necrotizing fasciitis: case report and review of literature. Acta Chir Belg 2007; 107: 29-36.
41. van Langevelde P, van Dissel JT, Meurs CJ et al. Combination of flucloxacillin and gentamicin inhibits toxic shock syndrome toxin production by Staphylococcus aureus in both logarithmic and stationary phases of growth. Antimicrob Agents Chemother 1997; 41: 1682-5.
42. Turner CE, Kurupati P, Jones MD et al. Emerging role of the interleukin-cleaving enzyme SpyCEP in clinical Streptococcus pyogenes infection. J Infect Dis 2009; 200: 555-63.
43. Gordon RJ, Lowy FD. Pathogenesis of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2008; Suppl 5: S350-9.
44. Zetola N, Francis JS, Nuermberger EL et al. Community-acquired methicillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis 2005; 5: 275-86.
45. Monecke S, Slickers P, Ellington MJ et al. High diversity of Panton-Valentine leukocidin-positive, methicillin-susceptible isolates of Staphylococcus aureus and implications for the evolution of community-associated methicillin-resistant S. aureus. Clin Microbiol Infect 2007; 13: 1157-64.
46. Stevens DL, Ma Y, Salmi DB et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 2007; 195: 2-11.
47. Dumitrescu O, Boisset S, Badiou C et al. Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin. Antimicrob Agents Chemother 2007; 51: 1515-9.
48. Proft T, Sriskandan S, Yang L et al. Superantigens and streptococcal toxic shock syndrome. Emerg Infect Dis 2003; 9: 1211-8.
49. Pavia AT, Bryan JA, Maher KL et al. Vibrio carchariae infection after a shark bite. Ann Intern Med 1989; 111: 85-6.
50. Jorge MT, De S, Nishioka A et al. Aeromonas hydrophila soft tissue infection as a complication of snake bite: report of three cases. Ann Imp Med Parasitol 1998; 92: 213-7.
51. Hertner G. Caiman bite. Wilderness Environ Med 2006; 17: 267-70.
52. Talan DA, Abrahamian FM, Moran GJ et al. Emergency Medicine Human Bite Infection Study Group. Clinical presentation and bacteriologic analysis of infected human bites in patients presenting to emergency departments. Clin Infect Dis 2003; 37: 1481-9.
53. Morgan M, Palmer J. Dog bites. BMJ 2007; 334: 413-7.
54. Holm M, Tarnvik H. Hospitalisation due to Pasteurella multocida-infected animal bite wounds: correlation with inadequate primary antibiotic medication. Scand J Infect Dis 2000; 32: 181-3.
55. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993; 328: 1323-32.
56. Jones ME, Karlowsky JA, Draghi DC et al. Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. Int J Antimicrob Agents 2003; 22: 406-19.
57. Cenizal MJ, Skiest D, Luber S et al. Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51: 2628-30.
58. Hyun DY, Mason EO, Forbes A et al. Trimethoprim-sulfamethoxazole or clindamycin for treatment of community-acquired methicillin-resistant Staphylococcus aureus skin and soft tissue infections. Pediatr Infect Dis J 2009; 28: 57-9.
59. Stevens DL, Smith LG, Bruss JB et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000; 44: 3408-13.
60. Stevens DL, Herr D, Lampiris H et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34: 1481-90.
61. Weigelt J, Itani K, Stevens D et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005; 49: 2260-6.
62. Wilcox M, Nathwani D, Dryden M. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections. J Antimicrob Chemother 2004; 53: 335-44.
63. Itani K, Dryden MS, Bhattacharyya H et al. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be due to methicillin-resistant Staphylococcus aureus. Am J Surg 2010; 199: 804-16.
64. Sharpe JN, Shively EH, Polk HC et al. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg 2005; 189: 425-8.
65. Lipsky BA, Itani K, Norden C et al. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis 2004; 38: 17-24.
66. Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptide or b-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 2008; 8: 53-66.
67. Ellis-Grosse EJ, Babinchak T, Dartois N et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of double-blind phase comparison studies with vancomycin-aztreonam. Clin InfDis 2005; 41: S3-53.
68. Florescu I, Beuran M, Dimov R et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother 2008; Suppl 1: i17-28.
69. May AJ, Stafford RE, Bulger EM et al. Treatment of complicated skin and soft tissue infections. Surg Infect 2009; 10: 467-99.
70. Hawkey PM. Pre-clinical experience with daptomycin. J Antimicrob Chemother 2008; Suppl 3: iii7-14.
71. Arbeit RD, Maki D, Tally FP etal. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38: 1673-81.
72. Woodcock KM, Andrews JM, Boswell FJ et al. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother 1997; 41: 101-6.
73. Giordano P, Song J, Pertel P et al. Sequential intravenous/PO moxifloxacin versus intravenous pipericillin-tazobactam followed by PO amoxicillin/clavulanate for the treatment of complicated skin and skin structure infection. Int J Antimicrob Agents 2005; 26: 357-65.
74. Gyssens IC, Dryden M, Kujath P et al. Efficacy of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of major abscess: results of the RELIEF study. In: European Congress of Clinical Microbiology and Infectious Diseases, Helsinki, 20Poster 17European Society for Clinical Microbiology and Infectious Diseases.
75. Gyssens IC, Dryden M, Kujath Pet al. Efficacy of IV/PO moxifloxacin in thetreatment of complicated skin and skin structure infections: results of the RELIEF study. In: European Congress of Clinical Microbiology and Infectious Diseases, Helsinki, 20Poster 17European Society for Clinical Microbiology and Infectious Diseases.
76. Schaper N, Dryden M, Kujath P et al. Efficacy of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin-clavulanate in the treatment of diabetic foot infections: results of the RELIEF study. In: European Congress of Clinical Microbiology and Infectious Diseases, Vienna 20Poster 15European Society for Clinical Microbiology and Infectious Diseases.
77. Edmiston CE, Krepel CJ, Seabrook GR et al. In vitro activities of moxifloxacin against 9aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob Agents Chemother 2004; 48: 1012-6.
78. Jacobs E, Dalhoff A, Korfmann G. Susceptibility pattern of bacterial isolates from hospitalised patients with respiratory tract infections (RTI), (moxikativ study). Int J Antimicrob Agents 2009; 33: 52-7.
79. Shopsin B, Zhao X, Kreiswirth BN. et al. Are the new quinolones appropriate treatment for community-acquired methicillin-resistant Staphylococcus aureus? Int J Antimicrob Agents 2004; 24: 32-4.